A revised mathematical treatment of the calibration line intercept has been published for in vivo bone lead measurements using 109 Cd-based K-shell x-ray fluorescence. The revised calibration line treatment prompts changes, presented herein, to the method for calculating the measurement uncertainty.
Introduction
Lead (Pb) is a ubiquitous toxin that has several health effects on humans. Monitoring of lead exposure is usually performed via measuring lead in whole blood, but the biological residence time of lead in blood is approximately 36 days (Rabinowitz et al 1976) . The majority of the human body burden of lead does not reside in blood but in the skeleton (Barry and Mossman 1970 , Barry 1975 , 1981 , wherein the biological residence time is of the order of years (Rabinowitz et al 1976 , Gerhardsson et al 1993 , Chettle 1995 , Börjesson et al 1997 , Brito et al 2000 . Lead in bone is thus a measure of long-term lead exposure (Somervaille et al 1988) .
The in vivo measurement of lead in bone using K-shell x-ray fluorescence (XRF) is a well-established (Ahlgren et al 1976) but still developing technique (Todd et al 2001a , 2001b . The present paper applies only to the method wherein the 88.034 keV γ -rays from 109 Cd are used to fluoresce the K-shell x-rays of lead. Usually the K α 1 and K α 2 peaks are used to derive an estimate of either the amplitude or the area of the K α 1 . Similarly, the K β 1 is estimated from the K β 1 and K β 3 peaks. These estimates are then used to calculate the in vivo lead concentration. The 109 Cd γ -rays can also undergo coherent scatter primarily off the calcium, phosphorous and oxygen atoms in the bone, giving rise to a peak of coherently scattered photons in the spectrum of scattered radiation. In the 109 Cd-based KXRF method, the ratios of the x-ray peak signals (areas or amplitudes), x i , to the coherent peak signal, coh, are treated as the measurement system responses (Somervaille et al 1985 , Todd 2000c . The use of these ratios renders the responses independent of several factors, principally the source-to-skin distance, overlying tissue thickness, bone shape, bone size, bone orientation and minor subject movement (Chettle et al 1991) .
Lead-doped, hydrated plaster-of-Paris (CaSO 4 .2H 2 O) phantoms are used for calibration. From these, the responses (from each x-ray, i) from an in vivo subject can be converted into estimates of the in vivo lead concentration, [Pb] i (an expression for which follows), which are then combined into a single, inverse-variance-weighted-mean estimate of the concentration, [Pb] µ , where [Pb] 
(
The uncertainty in [Pb] µ , σ [Pb] µ , is given by
The coherent scatter normalization introduces the need for a matrix 'correction' that takes into account the different coherent scattering cross sections of the phantom and the human (in vivo bone) matrices (Somervaille et al 1985 , Todd 2000c . The coherent correction factor, k, is the ratio of the coherent scattering cross sections for the two matrices. k is a function of energy and angle but, for purposes of this discussion, can be considered to be a constant. The matrix correction yields in vivo results that have units of µg of lead per gram of bone mineral (hereafter µg g −1 ). Formulae for [Pb] i and the uncertainty therein, σ (the latter derived from a variance propagation approach), were in use for several years before first being published (Gordon et al 1994) . Typographical errors in the published paper were reported (Todd 2000a (Todd , 2000b . In the original method (Gordon et al 1994) , the phantom calibration line intercept, C i , is always subtracted from the in vivo response: [Pb] Since then, a description of the physical origins of C i has been reported (Todd 2000d ). In brief, C i can arise from one or more sources: trace-level lead contamination of the plaster of Paris, plaster-of-Paris impurities other than lead, external lead contamination of the phantoms and/or measurement system from environmental sources, contaminating lead signal(s) from non-phantom items (e.g. chairs, floor tiles, lead paint on walls) and any 'offset' in the peak extraction program that results in overestimation of small, but non-zero peak sizes. These different potential sources of C i suggest different handling of C i , and it was therefore proposed (Todd 2000d ) that the treatment of C i be modified to take into account the source of C i : (a) to stop measurements (i.e. produce no result) if C i is significantly less than zero (because an error in the measurement process is indicated thereby); (b) to calculate the calibration line passing through the origin if C i is not significantly different from zero; and (c) to calculate the calibration line with a non-zero intercept only when C i is significantly greater than zero. For (a), no calculation of [Pb] i should be performed; for (b) and (c), it was proposed that, in contrast to the original method, C i not be subtracted from the in vivo signal, giving [Pb] 
In 2001, a 'correction' was published (Kondrashov and Rothenberg 2001) to the method wherein the intercept was always subtracted (Gordon et al 1994) . The correction is valid if the intercept continues to be taken into account. However, as indicated above, advocated previously and reiterated recently (Todd 2000a , 2000b , 2000d , Todd et al 2002 , the use of equation (2) is normally to be preferred because it reduces the possibility of bias in the estimate of lead concentration.
The revised treatment of C i (Todd 2000d ) affects the calculation of σ
, formulae for which were not presented with the revised treatment of C i and are therefore presented here. [Pb] i , σ [Pb] (2), we start from the generalized formula for the variance in Y = f (X i ) (wherein X i is a generalized argument and not an x-ray size, x i ):
Methods

The uncertainty in
The covariances between x i , coh and m i are all assumed to be zero (Gordon et al 1994 , Todd 2000a , 2000b :
For the 'high' and 'low' bone lead in vivo subjects of Gordon et al, the values of σ [Pb] i , derived from equation (4), are shown in tables 1 and 2 respectively. For interest only, tables 1 and 2 also show the σ [Pb] i reported by Gordon et al, which differ by only a small amount (−0.03 to 0.33 µg g −1 ) from those obtained using the revised treatment of C i .
The covariance between individual estimates of concentration, σ
There is a covariance between [Pb] i and [Pb] 
, that arises because both [Pb] i and [Pb] j depend on the same coh and which contributes to σ
To calculate the magnitude of this contribution, we start from a general expression that allows for a statistically independent coherent peak signal, coh i, for each x-ray: [Pb] i from Gordon et al overestimates σ [Pb] i 0.004 −0.028 0.013 0.091 from the modified treatment by (µg g −1 ) σ [Pb] i from Gordon et al overestimates σ [Pb] i 0.1 −0.2 0.2 0.8 from the modified treatment by (%) [Pb] i from modified treatment of C i 3.954 11.382 5.131 9.776 σ [Pb] i from Gordon et al overestimates σ [Pb] i 0.136 0.092 0.142 0.326 from the modified treatment by (µg g −1 ) σ [Pb] i from Gordon et al overestimates σ [Pb] i 3.4 0.8 2.8 3.3 from the modified treatment by (%) Applying the same generalized formula for the variance (equation (3)) (wherein the σ 2 [Pb] i are the weighting factors and can be considered constants for the purposes of this argument), we obtain:
for which we need the partial differentials:
If all the coh i are equal (i.e. the same single, coherent peak), then
which gives an expression for σ 2 [Pb] µ that contains both diagonal and non-diagonal elements:
The contribution to the measurement uncertainty arising from σ
It should be noted that the above term differs from the term given by Gordon et al (their equation (10)) by a factor of 2
2 , a typographical error in Gordon et al that has not previously been reported. It should also be noted that Todd's 'guess' of how the covariance term of Gordon et al was arrived at (Todd 2000a (Todd , 2000b ) is incorrect. [Pb] µ and σ [Pb] µ Table 3 shows that σ [Pb] µ for the revised treatment of C i (i.e. calculated from equation (5)) differs from that reported by Gordon et al by between 0.005 and 0.088 µg g −1 : far less than the measurement uncertainty itself (3.404 and 2.885 µg g −1 for subjects B and C, respectively). The effect of the modified treatment of C i on [Pb] µ can be larger and, for the calibration lines of Gordon et al, is greater than the measurement uncertainty. Of course, the effect of the modified treatment of C i depends on the magnitude of C i and can be zero if C i for a particular phantom calibration line is zero.
The effect of the revised treatment of C i on
If, as is usual, only the K α 1 and K β 1 are used to estimate the in vivo lead concentration, the effect of the modified treatment of C i is diminished for the calibration lines of Gordon et al (table 3 also shows [Pb] µ and σ [Pb] µ calculated from only these two peaks), and [Pb] µ for the modified treatment of C i no longer differs from that of Gordon et al by more than σ [Pb] µ . ). These values for [Pb] µ and σ [Pb] µ are reassuringly consistent with those given in table 3 for the calculations based on two (of the four fitted) peaks. [Pb] µ by 0.26% for subject B and by 0.002% for subject C) and for the modified treatment of C i (wherein σ 2 [Pb] i [Pb] j increases σ [Pb] µ by 0.5% for subject B and by 0.004% for subject C).
Further work
A comparison between the standard deviation of repeated measurements and the average value of σ [Pb] µ (Todd et al 2000) showed that the latter underestimated the former, often significantly. The differences may arise from contributions to the uncertainty that are not accounted for in the formulae for the uncertainty from, for example, short-term and long-term reproducibility. Further work is in progress to identify the importance of such components. The differences between the standard deviation of repeated measurements and the uncertainty derived from counting statistics and calibration are substantially greater, and therefore substantially more important, than the effect of the formulae presented here. The revised formulae are nevertheless necessary for a consistent method.
Conclusion
Formulae for the uncertainty in the predicted lead concentration derived from bone lead xray fluorescence spectra are presented for a previously published revised treatment of the calibration line intercept. The revised treatment, although appropriate, has little effect on the calculated uncertainty but can have a larger effect on the calculated concentration. Further work is required to determine sources of measurement uncertainty not reflected in the formulation.
